Cargando…

Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials

BACKGROUND: Alzheimer’s disease (AD) is associated with considerable costs and has a significant impact on health and social care systems. OBJECTIVE: This study assessed whether baseline comorbidities present in 2,594 patients with AD participating in two semagacestat randomized placebo-controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kahle-Wrobleski, Kristin, Fillit, Howard, Kurlander, Jonathan, Reed, Catherine, Belger, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646926/ https://www.ncbi.nlm.nih.gov/pubmed/25410743 http://dx.doi.org/10.1007/s10198-014-0648-7

Ejemplares similares

Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
por: Reed, Catherine, et al.
Publicado: (2018)

How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study
por: Belger, Mark, et al.
Publicado: (2016)

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
por: Spiegel, René, et al.
Publicado: (2013)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes
por: Jones, Roy W., et al.
Publicado: (2017)

Detection, diagnosis, and treatment of Alzheimer’s disease dementia stratified by severity as reported by caregivers in Japan
por: Montgomery, William, et al.
Publicado: (2018)

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists
por: Kirson, Noam Y., et al.
Publicado: (2016)

Alzheimer’s disease severity and its association with patient and caregiver quality of life in Japan: results of a community-based survey
por: Montgomery, William, et al.
Publicado: (2018)

Impact of caring for persons with Alzheimer’s disease or dementia on caregivers’ health outcomes: findings from a community based survey in Japan
por: Goren, Amir, et al.
Publicado: (2016)

Understanding the Complexities of Functional Ability in Alzheimer’s Disease: More Than Just Basic and Instrumental Factors
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2014)

Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study
por: Lenox-Smith, Alan, et al.
Publicado: (2016)

Using U.S. Medicare records to evaluate the indirect health effects on spouses: a case study in Alzheimer’s disease patients
por: Gilden, Daniel M, et al.
Publicado: (2014)

Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer’s disease
por: Lebrec, Jeremie, et al.
Publicado: (2016)

Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population
por: Happich, Michael, et al.
Publicado: (2016)

Potential cost savings to be made by slowing cognitive decline in mild Alzheimer’s disease dementia using a model derived from the UK GERAS observational study
por: Lenox-Smith, Alan, et al.
Publicado: (2018)

The influence of caregivers and behavioral and psychological symptoms on nursing home placement of persons with Alzheimer’s disease: A matched case–control study
por: Porter, Candace N, et al.
Publicado: (2016)

Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer’s Disease
por: Kirson, Noam Y., et al.
Publicado: (2017)

Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model
por: Furiak, Nicolas M, et al.
Publicado: (2010)

Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer’s Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study
por: Nakanishi, Miharu, et al.
Publicado: (2020)

Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia
por: Belger, Mark, et al.
Publicado: (2018)

Novel strategies for the prevention of dementia from Alzheimer's disease
por: Shineman, Diana W., et al.
Publicado: (2009)

Multidomain trials to prevent dementia: addressing methodological challenges
por: Montero-Odasso, Manuel, et al.
Publicado: (2022)

Translating the biology of aging into novel therapeutics for Alzheimer disease
por: Hara, Yuko, et al.
Publicado: (2019)

Meeting the unique challenges of drug discovery for neurodegenerative diseases
por: Shineman, Diana W, et al.
Publicado: (2009)

Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
por: Lane, Rachel F, et al.
Publicado: (2013)

Testing the “RCT augmentation” methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectiveness
por: Nordon, Clementine, et al.
Publicado: (2023)

Methodological considerations in cost of illness studies on Alzheimer disease
por: Costa, Nagede, et al.
Publicado: (2012)

A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA
por: Lee, Linda H, et al.
Publicado: (2010)

Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges
por: Mason, S. E., et al.
Publicado: (2010)

Undertaking a randomised controlled trial in the police setting: methodological and practical challenges
por: Scantlebury, Arabella, et al.
Publicado: (2017)

Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias
por: Lane, Rachel F, et al.
Publicado: (2011)

Drug safety assessment in clinical trials: methodological challenges and opportunities
por: Singh, Sonal, et al.
Publicado: (2012)

Methodological Challenges in Online Trials
por: Murray, Elizabeth, et al.
Publicado: (2009)

Cost-effectiveness models for Alzheimer’s disease and related dementias: IPECAD modeling workshop cross-comparison challenge
por: Handels, Ron L.H., et al.
Publicado: (2023)

Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)(1)
por: Robinson, Rebecca L., et al.
Publicado: (2020)

Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer’s Disease Patients
por: Qureshi, Zaina P., et al.
Publicado: (2021)

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
por: Shineman, Diana W, et al.
Publicado: (2013)

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey
por: Andrews, J. Scott, et al.
Publicado: (2016)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery
por: Friedman, Lauren G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v3jaopjr4uduavpurh1tg9nvu9